{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:33:51Z","timestamp":1793068431764,"version":"4.5.0"},"reference-count":37,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,11,6]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.2967\/jnumed.125.270654","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:50:14Z","timestamp":1765471814000},"page":"416-422","source":"Crossref","is-referenced-by-count":6,"title":["Targeted \u03b2\n                    <sup>\u2212<\/sup>\n                    -Particle Plus Conversion and Auger-Electron Therapy with\n                    <sup>161<\/sup>\n                    Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study"],"prefix":"10.2967","volume":"67","author":[{"given":"Julia G.","family":"Fricke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Westerbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Favaretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume P.","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Geistlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Borgna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Fani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2026030205300691000_67.3.416.1","doi-asserted-by":"crossref","first-page":"109085","DOI":"10.1016\/j.apradiso.2020.109085","article-title":"Determination of 161Tb half-life by three measurement methods","volume":"159","author":"Duran","year":"2020","journal-title":"Appl Radiat Isot."},{"key":"2026030205300691000_67.3.416.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2011.02.007"},{"key":"2026030205300691000_67.3.416.3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40658-020-00314-x","article-title":"Establishment of a clinical SPECT\/CT protocol for imaging of 161Tb","volume":"7","author":"Marin","year":"2020","journal-title":"EJNMMI Phys."},{"key":"2026030205300691000_67.3.416.4","doi-asserted-by":"crossref","unstructured":"Westerbergh F . Image-based dosimetry in targeted radionuclide therapy with terbium-161: from technical foundations to clinical application [doctoral thesis]. Gothenburg University Library website. https:\/\/gupea.ub.gu.se\/handle\/2077\/85342. Updated May 15, 2025. Accessed November 24, 2025.","DOI":"10.1186\/s13550-025-01326-3"},{"key":"2026030205300691000_67.3.416.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267873"},{"key":"2026030205300691000_67.3.416.6","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-019-0075-2"},{"key":"2026030205300691000_67.3.416.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01663-7"},{"key":"2026030205300691000_67.3.416.8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40658-024-00696-2","article-title":"Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases","volume":"11","author":"De Nardo","year":"2024","journal-title":"EJNMMI Phys."},{"key":"2026030205300691000_67.3.416.9","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.7150\/thno.95436","article-title":"Palladium-103 (103Pd\/103mRh), a promising Auger-electron emitter for targeted radionuclide therapy of disseminated tumor cells: absorbed doses in single cells and clusters, with comparison to 177Lu and 161Tb","volume":"14","author":"Hindie","year":"2024","journal-title":"Theranostics."},{"key":"2026030205300691000_67.3.416.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2026030205300691000_67.3.416.11","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2026030205300691000_67.3.416.12","unstructured":"COMPETE trial data shows 177Lu-edotreotide improves progression-free survival in SSTR-GEP-NETs. Applied Radiology website. https:\/\/appliedradiology.com\/articles\/compete-trial-data-shows-177lu-edotreotide-improves-progression-free-survival-in-sstr-gep-nets. Published March 13, 2025. Accessed November 24, 2025."},{"key":"2026030205300691000_67.3.416.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264043"},{"key":"2026030205300691000_67.3.416.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.190124"},{"key":"2026030205300691000_67.3.416.15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/ph14121265","article-title":"Distinct in\u00a0vitro binding profile of the somatostatin receptor subtype 2 antagonist [177Lu]Lu-OPS201 compared to the agonist [177Lu]Lu-DOTA-TATE","volume":"14","author":"Mansi","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026030205300691000_67.3.416.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.138834"},{"key":"2026030205300691000_67.3.416.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.167007"},{"key":"2026030205300691000_67.3.416.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191684"},{"key":"2026030205300691000_67.3.416.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258889"},{"key":"2026030205300691000_67.3.416.20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00259-023-06383-1","article-title":"A phase I\/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours","volume":"51","author":"Wild","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030205300691000_67.3.416.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266817"},{"key":"2026030205300691000_67.3.416.22","doi-asserted-by":"publisher","DOI":"10.1667\/RR1359.1"},{"key":"2026030205300691000_67.3.416.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05564-0"},{"key":"2026030205300691000_67.3.416.24","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00259-024-06641-w","article-title":"First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum","volume":"51","author":"Fricke","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030205300691000_67.3.416.25","doi-asserted-by":"crossref","first-page":"e06097","DOI":"10.1016\/j.heliyon.2021.e06097","article-title":"Modelling of energy-dependent spectral resolution for SPECT Monte Carlo simulations using SIMIND","volume":"7","author":"Morphis","year":"2021","journal-title":"Heliyon."},{"key":"2026030205300691000_67.3.416.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265484"},{"key":"2026030205300691000_67.3.416.27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40658-022-00495-7","article-title":"Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90","volume":"9","author":"Hemmingsson","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2026030205300691000_67.3.416.28","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/56\/8\/001"},{"key":"2026030205300691000_67.3.416.29","doi-asserted-by":"crossref","first-page":"8794","DOI":"10.1088\/1361-6560\/61\/24\/8794","article-title":"An image-based skeletal dosimetry model for the ICRP reference adult female: internal electron sources","volume":"61","author":"O\u2019Reilly","year":"2016","journal-title":"Phys Med Biol."},{"key":"2026030205300691000_67.3.416.30","first-page":"7","article-title":"Nuclear decay data for dosimetric calculations. ICRP publication 107","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann ICRP."},{"key":"2026030205300691000_67.3.416.31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41181-019-0063-6","article-title":"Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy","volume":"4","author":"Gracheva","year":"2019","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026030205300691000_67.3.416.32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-017-0201-8","article-title":"Fast GPU-based Monte Carlo code for SPECT\/CT reconstructions generates improved 177Lu images","volume":"5","author":"Ryden","year":"2018","journal-title":"EJNMMI Phys."},{"key":"2026030205300691000_67.3.416.33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40658-023-00589-w","article-title":"Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection","volume":"10","author":"Verburg","year":"2023","journal-title":"EJNMMI Phys."},{"key":"2026030205300691000_67.3.416.34","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1007\/s00259-024-06682-1","article-title":"Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours","volume":"51","author":"Schurrle","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030205300691000_67.3.416.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1026"},{"key":"2026030205300691000_67.3.416.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00772-X"},{"key":"2026030205300691000_67.3.416.37","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.7150\/thno.113354","article-title":"Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells","volume":"15","author":"Nguyen","year":"2025","journal-title":"Theranostics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:30:41Z","timestamp":1772458241000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.2967\/jnumed.125.270654"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270654","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}